The DOI matches its Crossref record.
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Abstract
PURPOSE: Since liposomal encapsulation of anticancer drugs may enhance antitumor activity while reducing toxicity in vitro, we evaluated liposomally encapsulated daunorubucin (DaunoXome; Vestar, Inc, San Dimas, CA) for safety, pharmacokinetics, and potential efficacy in patients with AIDS-related Kaposi's sarcoma (AIDS-KS). PATIENTS AND METHODS: Forty patients with advanced AIDS-KS were accrued. Successive cohorts received DaunoXome at doses of 10, 20, 30, and 40 mg/m2 given once every 3 weeks, and 40, 50, and 60 mg/m2 given once every 2 weeks. Selected KS and solid-tumor patients underwent pharmacokinetic evaluation. RESULTS: The area under the plasma concentration curve (AUC) ranged from 16.9 micrograms.h/mL to 375.3 micrograms./mL and the alpha half-life ranged from 7.8 to 8.3 hours at 10 mg/m2 to 60 mg/m2, respectively. Both pharmacokinetic profiles were significantly better compared with free daunorubicin. DaunoXome was well tolerated with no significant alopecia, mucositis, or vomiting. Neutropenia (< 1,000/microL occurred in 17% of cycles and was severe (< 500/microL) in only 2%. Anemia and thrombocytopenia were uncommon. Other adverse events included mild to moderate fatigue, nausea, and diarrhea. Even after cumulative doses greater than 1,000 mg/m2, no significant declines in cardiac function were observed. Twenty-two patients who received 50 and 60 mg/m2 were assessable for tumor response; 12 (55%) had a partial response (PR) or clinical complete response (CR). The median survival duration in all patients was 9 months. Prognostic factors for short survival were low CD4 lymphocyte counts (P = .004) and prior anthracycline therapy (P = .02). CONCLUSION: DaunoXome has an improved pharmacokinetic profile compared with free daunorubicin, and is well tolerated. DaunoXome can be given safely at doses up to 60 mg/m2 every 2 weeks and has significant antitumor activity in patients with AIDS-KS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Novel applications of liposomes
Lasic, D. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01220-7 · Cited by 867
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Muller, R. H., & Keck, C. M. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.06.007 · Cited by 819
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Engineering liposomes for drug delivery: progress and problems
Gregoriadis, G. (1995) · Trends in Biotechnology · doi:10.1016/s0167-7799(00)89017-4 · Cited by 626
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Nanostructured lipid carriers system: Recent advances in drug delivery
Iqbal, M. A., Md, S., Sahni, J. K., Baboota, S., Dang, S., & Ali, J. (2012) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.716845 · Cited by 436
Lipid nanoparticles for parenteral delivery of actives
Joshi, M. D., & Müller, R. H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.003 · Cited by 433
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Self-citationLyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., & Gabizon, A. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z · Cited by 385
Liposomen: Möglichkeiten der Medikamentenfreisetzung
Allen, T. M. (1997) · Drugs · doi:10.2165/00003495-199700544-00004 · Cited by 279
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
Gopi, S., & Balakrishnan, P. (2021) · Journal of Liposome Research · doi:10.1080/08982104.2020.1820521 · Cited by 94
Axial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives
Kiaie, S. H., Mojarad-Jabali, S., Khaleseh, F., Allahyari, S., Taheri, E., Zakeri-Milani, P., & Valizadeh, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119269 · Cited by 87
Metadata
- Authors
- Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., & Levine, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-04
- Volume
- 13
- Issue
- 4
- Pages
- 996-1003
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1956382989
- Cited by
- 242
- References
- 0
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.